Evidence map›Paper›PMID 30778081›Full record

SynthesisScientific reports2019

The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis.

Kancheng He, Huating Hu, Senlin Ye, Haohui Wang, Rongrong Cui, Lu Yi

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Kancheng HeDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Huating HuThe First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, China.
Senlin YeDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Haohui WangDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Rongrong CuiInstitute of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. rongrongcui@csu.edu.cn.
Lu YiDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. yilu9999@csu.edu.cn.
Second Xiangya Hospital of Central South University · CNCentral South University · CNFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between metformin and prostate cancer (PCa) remains controversial. To clarify this association, the PubMed, Embase and Cochrane library databases were systematically searched from their inception dates to May 23, 2018, using the keywords "metformin" and "prostate cancer" to identify the related studies. The results included incidence, overall survival (OS), PCa-specific survival (CSS) and recurrence-free survival (RFS), which were measured as hazard ratios (HR) with a 95% confidence interval (95% CI) using Review Manager 5.3 software. A total of 30 cohort studies, including 1,660,795 patients were included in this study. Our study revealed that metformin treatment improves OS, CSS and RFS in PCa (HR = 0.72, 95% CI: 0.59-0.88, P = 0.001; HR = 0.78, 95% CI: 0.64-0.94, P = 0.009; and HR = 0.60, 95% CI: 0.42-0.87 P = 0.006, respectively) compared with non-metformin treatment. However, metformin usage did not reduce the incidence of PCa (HR = 0.86, 95% CI: 0.55-1.34, P = 0.51). In conclusion, compared with non-metformin treatment, metformin therapy can significantly improve OS, CSS and RFS in PCa patients. No association was noted between metformin therapy and PCa incidence. This study indicates a useful direction for the clinical treatment of PCa.

Indexed as

Disease SusceptibilityHumansHypoglycemic AgentsIncidenceMaleMetforminPrognosisProportional Hazards ModelsProstatic NeoplasmsSurvival AnalysisHypoglycemic AgentsMetformin

Identifiers

PMID30778081
PMCPMC6379374
OpenAlexW2917539417

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.